Horizon gains first FDA approval in thyroid eye disease

With FDA’s approval of Horizon’s thyroid eye disease drug -- the first for the indication -- the company is looking ahead to add to its rare disease pipeline through deal-making.

The approval comes ahead of the March 8 PDUFA date for Tepezza teprotumumab-trbw, continuing the recent trend of speedy FDA approvals (see “FDA Approvals in 2019”)...